Table S1 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations

Patient characteristics</p

Fig. S15 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations

Hazard ratios with deviation for specific signatures detected in the myeloid subtype of LUAD. The relationship between increased and decreased expression of signatures and event-free survival using transcriptome data from TCGA NSCLC was plotted. (a) hallmark gene set. (b) GO set.</p

TABLE 1 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations

Univariate and multivariate analyses of prognostic factors in LUAD and LUSQ</p

Fig. S8 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations

IHC of LUAD and LUSQ tissues of a representative case from immune subtypes. The antibodies against CD20 and FOXP3 are used in LUAD (a) and LUSQ tissues (b).</p

Fig. S9 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations

CD33 IHC of LUAD and LUSQ tissues of a representative case from immune subtypes. (a) LUAD. (b)LUSQ. The number is the ratio of CD33 positive staining area per tissue area (percentage).</p

Fig. S14 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations

Activated and suppressed pathways identified by GSEA with GO gene set in respective immune subtypes. (a, b) Heatmap representing top scored pathways enriched in genes showing commonly increased and decreased expression in respective immune subtypes in LUAD (a) and LUSQ (b). Top signaling pathways for genes showing increased expression are presented in red and those for genes showing decreased expression are presented in blue. (c, d) Running enrichment score with GO gene set of blood vessel morphogenesis, epidermis development, keratinocyte differentiation, and T cell activation signatures as the activated pathways in respective immune subtypes of LUAD (c) and LUSQ (d).</p

Fig. S6 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations

Relationship between the number of immune cell types and clinicopathological factors. Cells in the matrix represent the 1-Pearson correlation coefficient between cell density of the indicated immune cell composition and clinicopathological factors in LUAD (left) and LUSQ (right). * p<0.05.</p

Fig. S5 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations

Relation of immune cell types with WHO classification. LUAD (n=82) (lepidic; n=2, acinar; n=7, papillary; n=39, micropapillary; n=11, solid; n=15, IMA; n=8) and LUSQ (n=50) (non-keratinizing; n=6, keratinizing; n=42, basaloid; n=2). (a–d) �45 of immune cell type (a), �4 of CD4+ T cell subset (b), �8 of CD8+ T cell subset (c), and %myeloid of myeloid cell type (d) are presented following the WHO classification of LUAD and LUSQ. ns; not significant. * p<0.05. **P<0.01. ***P<0.001.</p